Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem’s ARDS Associated With COVID-19 Program to Mexico
29 déc. 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study
09 déc. 2020 04h00 HE
|
Pluristem Therapeutics, Inc.
The CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the...
Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the ASH Annual Meeting
18 nov. 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
PLX-R18 demonstrated significant clinical improvements in Hb, ANC, and PLT among the high-dose cohortPLX-R18 was found to be safe and well-toleratedTopline results from the full Phase I clinical trial...
World Experts in Infectious Diseases & Critical Care Form Pluristem’s COVID-19 Steering Committee
20 oct. 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study
13 oct. 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
07 oct. 2020 02h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event
01 oct. 2020 03h00 HE
|
Pluristem Therapeutics, Inc.
The Malta Conferences address the shared desire to improve quality of life and political stability in the Middle East through scientific collaboration HAIFA, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE)...
Pluristem CEO Issues Shareholder Update
15 sept. 2020 07h30 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial
27 août 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study
19 août 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...